Summary:
Thyme Care, a cancer care navigation startup, raised $95 million in Series C funding.
The funding will be used to further develop Thyme Care's value-based care model.
Thyme Care offers incentive payments to providers and keeps a cut of insurers' savings.
Investors are increasingly interested in cost-effective and high-quality cancer care.
Thyme Care's innovative approach is attracting prominent investors such as Andreessen Horowitz and CVS Health Ventures.
Thyme Care Secures $95 Million to Disrupt Cancer Care
Thyme Care, a cancer care navigation startup, has raised a whopping $95 million in Series C funding led by Concord Health Partners. This investment comes on the heels of their $60 million Series B funding just a year ago, bringing their total funds to $178 million.
This significant investment highlights the growing interest in value-based cancer care, a model that aims to improve patient outcomes while simultaneously reducing costs. Thyme Care is uniquely positioned to address this challenge by offering incentive payments to providers and keeping a cut of insurers' savings.
The company's innovative approach has attracted prominent investors including Andreessen Horowitz, Foresite Capital, and CVS Health Ventures, demonstrating strong confidence in their vision for the future of cancer care.
Why the Focus on Cancer Care?
Cancer care in the US is a multi-billion dollar industry, with high costs and variable outcomes for patients. Thyme Care's mission to improve both cost-effectiveness and patient outcomes resonates with investors who see a vast opportunity for innovation in this critical area.
Comments